IndraLab
Statements
reach
"Inhibition of TrxR1 activity by the FDA-approved drug auranofin inhibits Nlrp3 activation in cultured macrophages and ameliorates hepatic injury in murine models of fibrosis.7–9,20
The objective of this study was to examine the effect of hepatocyte-specific deletion of TrxR1 (TrxR1 ) on hepatic inflammation, inflammasome activation, and injury during acute BDL-induced cholestatic injury."